title: Development-associated immunophenotypes reveal the heterogeneous and individualized early responses of adult B-acute lymphoblastic leukemia.
abstract: B cell acute lymphoblastic leukemia (B-ALL) exhibits phenotypes reminiscent of normal stages of B-cell development. As demonstrated by flow cytometry, the immunophenotypes are able to determine the stages of B cell development. Multicolor flow cytometry (MFC) is more accurate at identifying cell populations. In this study, 9-color panels, including CD10, CD19, CD20, CD22, CD34, CD79a, CD179a, and IgM, which are sequentially expressed during B cell development, were designed to detect the leukemia cell subpopulations in adult B-ALL patients. In 23 patients at diagnosis, 192 heterogeneous subpopulations of leukemia cells were detected. Compared with their counterparts at diagnosis and after the 1st course of induction therapy, the responses of the subpopulations were also heterogeneous. In the CD10 population, the residual B cell subpopulations in the BCR/ABL patients were obviously reduced compared to those in the BCR/ABL patients. New subpopulations were detected in 22 of 23 patients and were primarily located in the CD34CD10 populations. Subpopulations of clonal evolution were heterogeneous after induction therapy. Our results suggest that the subpopulations in B-ALL patients should be dynamically monitored by development-associated immunophenotyping before, during, and after induction therapy and to predict the prognosis of the disease.
authors: Laboratory of Stem Cell Biology, State Key Laboratory of Biotherapy Department of Hematology Department of Laboratory Medicine, West China Hospital Collaborative Innovation Center for Biotherapy, Sichuan University, Chengdu, China.
authors: Hui-Fang
authors: HF
authors: Li
authors: Wen-Tong
authors: WT
authors: Meng
authors: Yong-Qian
authors: YQ
authors: Jia
authors: Neng-Gang
authors: NG
authors: Jiang
authors: Ting-Ting
authors: TT
authors: Zeng
authors: Yong-Mei
authors: YM
authors: Jin
authors: Qiao-Rong
authors: QR
authors: Huang
authors: Xue
authors: X
authors: Li
authors: Hong
authors: H
authors: Xu
authors: Xian-Ming
authors: XM
authors: Mo
mesh_terms: D000293:Adolescent; D000328:Adult; D018943:Anthracyclines / Q000008:administration & dosage; D018941:Antigens, CD19; D018951:Antigens, CD20 / Q000032:analysis; D018952:Antigens, CD34 / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001215:Asparaginase / Q000008:administration & dosage; D001402:B-Lymphocytes / Q000737:chemistry*; D051925:CD79 Antigens / Q000032:analysis; D005260:Female; D005434:Flow Cytometry / Q000379:methods; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D000068877:Imatinib Mesylate / Q000008:administration & dosage; D054444:Immunoglobulin Light Chains, Surrogate / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D016130:Immunophenotyping; D060828:Induction Chemotherapy; D008297:Male; D008875:Middle Aged; D015260:Neprilysin / Q000032:analysis; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology* / Q000473:pathology; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D051918:Sialic Acid Binding Ig-like Lectin 2 / Q000032:analysis; D014750:Vincristine / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D018943:Anthracyclines; D018941:Antigens, CD19; D018951:Antigens, CD20; D018952:Antigens, CD34; D051925:CD79 Antigens; D054444:Immunoglobulin Light Chains, Surrogate; D007075:Immunoglobulin M; D051918:Sialic Acid Binding Ig-like Lectin 2; C515639:VPREB1 protein, human; D014750:Vincristine; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; D015260:Neprilysin; D001215:Asparaginase; D011241:Prednisone